"Biontech" and "Pfizer" begin trials of the vaccine against "Omicron"

The German company "Biontech" and the American "Pfizer" company have started the first clinical study to test a vaccine designed to prevent the new corona mutant "Omicron".

The two companies announced that during this study, the safety, tolerability and efficacy of the candidate vaccine will be examined.

According to the data, the study will include about 1,420 people, who will be divided into three groups.

The first group will include about 600 people who, during the 90 to 180 days preceding the study, received two doses of the current vaccine against Corona, and will now receive one or two doses of the Omicron vaccine.

As for the second group, which will include approximately the same number, it will receive either a booster dose of the original vaccine or a dose of the Omicron vaccine, while the third group will include about 200 people who have not received an anti-Corona vaccine and have not yet been infected with Corona, and during the study they will receive three doses of the Omicron vaccine.

"The study is part of our scientific approach to developing a vaccine that provides similar protection against Omicron, as we observed with previous mutant, but at the same time its effectiveness lasts for a longer period," said Ugur Sahin, president of Biontech.

And the pharmaceutical company, which is based in the German city of Mainz, and its American partner announced about two weeks ago that they had already started producing a corona vaccine that was adapted to the Omicron mutant for later commercial use.

Piontech had stated that the two companies were "ready to supply the market by next March, once the approvals of the authorities are obtained."

Follow our latest local and sports news and the latest political and economic developments via Google news